Literature DB >> 3333846

Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain.

J Markussen1, P Hougaard, U Ribel, A R Sørensen, E Sørensen.   

Abstract

Hydrophilic insulins, more positively charged than human insulin at neutral pH, have been prepared by substitution with basic amino acids at the termini of the B-chain and by blocking the C-terminal carboxyl group of the B-chain. The isoelectric pH of the insulin is thereby moved from 5.4 towards physiological levels. Slightly acid solutions of derivatives, in which charge has been added in the C-terminus of the B-chain, have a prolonged action in vivo, in particular if the carboxyl group is blocked. It is found that the prolonged-acting hydrophilic insulins crystallize instantly when the pH is adjusted to 7. The prolonged action is ascribed to this readiness to crystallization combined with a low solubility, which may be further decreased by increased concentration of zinc ions. Hydrophobic insulins have a prolonged action independent of the site of substitution even if the derivative is soluble at physiological pH. Some derivatives were prepared from porcine insulin by tryptic transpeptidation. N-terminal B-chain substituted insulins were prepared by alkylation of a biosynthetic single-chain insulin precursor, followed by tryptic transpeptidation rendering the double chain insulin derivative. The observed blood glucose lowering in the rabbits implies that neither N- nor C-terminal B-chain substitution results in substantial deterioration of biological potency. An index for the degree of protraction based on the blood glucose data is used to compare the insulins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3333846     DOI: 10.1093/protein/1.3.205

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  9 in total

1.  Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Authors:  Nischay K Rege; Nalinda P Wickramasinghe; Alisar N Tustan; Nelson F B Phillips; Vivien C Yee; Faramarz Ismail-Beigi; Michael A Weiss
Journal:  J Biol Chem       Date:  2018-06-07       Impact factor: 5.157

Review 2.  The pursuit of perfect control in diabetes.

Authors:  J Pickup
Journal:  BMJ       Date:  1988-10-15

3.  Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs.

Authors:  J Markussen; S Havelund; P Kurtzhals; A S Andersen; J Halstrøm; E Hasselager; U D Larsen; U Ribel; L Schäffer; K Vad; I Jonassen
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

Review 4.  Advances in the treatment of diabetes mellitus in the elderly. Development of insulin analogues.

Authors:  B J Hoogwerf; A Mehta; S Reddy
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

5.  The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

Authors:  Svend Havelund; Anne Plum; Ulla Ribel; Ib Jonassen; Aage Vølund; Jan Markussen; Peter Kurtzhals
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

6.  Characterization of an insulin from the three-toed amphiuma (Amphibia: Urodela) with an N-terminally extended A-chain and high receptor-binding affinity.

Authors:  J M Conlon; E S Cavanaugh; D C Mynarcik; J Whittaker
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

7.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo.

Authors:  P Kurtzhals; S Havelund; I Jonassen; B Kiehr; U D Larsen; U Ribel; J Markussen
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

Review 8.  The evolution of insulin glargine and its continuing contribution to diabetes care.

Authors:  Rolf Hilgenfeld; Gerhard Seipke; Harald Berchtold; David R Owens
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

9.  Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.

Authors:  Leszek Nosek; Hans-Veit Coester; Carsten Roepstorff; Henrik F Thomsen; Niels R Kristensen; Hanne Haahr; Tim Heise
Journal:  Clin Drug Investig       Date:  2014-09       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.